AxoGen (AXGN) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and market opportunity

• Committed to making nerve repair a standard of care, restoring peripheral nerve function, and improving patient quality of life.

• Focused on advancing peripheral nerve care through innovation, education, and clinical leadership.

• Addressing a $5.6B US nerve care market with over 1.5 million annual injuries in extremities, breast reconstruction, oral/maxillofacial, and prostate surgery.

• Strategic plan targets 15–20% annual revenue growth from 2025–2028, with expansion into elective procedures and new markets like prostate.

• Commercial infrastructure and tailored messaging for each care pathway, with salesforce expansion to support growth.

Product innovation and regulatory milestones

• Avance Nerve Graft is the first FDA-approved biologic for nerve discontinuity repair, preserving native nerve architecture and supporting axonal regeneration.

• Achieved first-of-its-kind biologics license for nerve discontinuity treatment, setting a new industry standard.

• Comprehensive portfolio includes Avance, Axoguard, and Avive+ for various nerve repair needs.

• Biologics approval enables focus on a single quality system, improving operational efficiency and margins.

• Ongoing and planned R&D and clinical studies aim to improve ease of use, protection, and generate Level 1 evidence for standard of care adoption.

Commercial execution and growth drivers

• Double-digit growth in all markets, with elective procedures like breast and oral/maxillofacial growing at high double digits.

• Extremities remain the largest and most established business, with strong relationships and societal endorsements.

• Breast reconstruction (Resensation) is a high-growth area, with 70%-90% of the market potentially addressable.

• Prostate care pathway clinical program has completed patient enrollment, with results expected in late 2026.

• Sales representatives typically become productive within 6-9 months, contributing to financial break-even.